Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

In a mouse study, researchers found that zolpidem (Ambien), a common sleep aid, could prevent the brain from effectively ...

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...

Nootropics are touted as “smart drugs” meant to improve cognitive performance. But there’s a lot we still don’t know about ...

A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.